Senior Manager, Clinical Scientist, Genetics Medicine
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Senior Manager to join our Clinical Sciences team within Regeneron Genetics Medicine, supporting early clinical development in a fast-paced, collaborative environment. In this role, you will contribute to clinical strategy and study execution from the discovery phase through Proof of Concept, helping translate genetic insights into potential new treatments. You will collaborate closely with your supervisor, Clinical Trial Managers, and cross-functional study teams.
Job description
When & where
- Location: Tarrytown, NY, Warren, NJ, Cambridge, MA
- Work model/flexibility: Primarily On-site with hybrid flexibility
Discover your role
- Represent the clinical genetics medicine function on study teams, contributing medical and scientific expertise to compliant, high-quality trial execution
- Contribute to Clinical Study Concepts, protocols, and amendments, supported by literature research on indication selection, rationale, and endpoints
- Draft clinical sections of regulatory and clinical documents, including briefing books, IND/IMPD submissions, investigator’s brochures, consent forms, and study reports
- Review key study documents such as medical monitoring plans, statistical analysis plans, and data management materials
- Partner with Clinical Trial Managers to provide day-to-day clinical input and train study team and CRO personnel on clinical aspects of the trial
- Support medical monitoring, investigator queries, safety narratives, and trend analysis of safety and efficacy data
- Organize steering committees, advisory boards, data safety monitoring boards, and consultations with global subject matter experts
- Identify program, trial, and data risks and implement mitigation strategies, while ensuring compliance with FDA, EMEA, ICH, and GCP guidelines
This role requires
- Bachelor’s degree and 8+ years of clinical research/development experience
- Preferred: PhD, PharmD, or Master’s degree in a biomedical subject
- Training as a scientist in the pharmaceutical or biotechnology sector, or in an academic or clinical setting
- Effective verbal and written communication and presentation skills
- Ability to work productively in a fast-paced, collaborative environment
- Demonstrated or potential critical thinking skills and sound decision-making
- Preferred: Experience in early-phase development, including First-In-Human and Proof of Concept studies
Requirements
- Bachelor’s degree
- 8+ years of clinical research/development experience
- Training as a scientist in the pharmaceutical or biotechnology sector, or in an academic or clinical setting
- Effective verbal and written communication and presentation skills
- Ability to work productively in a fast-paced, collaborative environment
- Demonstrated or potential critical thinking skills and sound decision-making
- Preferred: PhD, PharmD, or Master’s degree in a biomedical subject
- Preferred: Experience in early-phase development, including First-In-Human and Proof of Concept studies
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.